All In Biotech

Drug Trial Radar · NCT01872598

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 721 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

721

Actual

Start

Jan 2012

Primary completion

Dec 2020

Study completion Dec 2020

Sponsor

Lead sponsor
AB ScienceIndustry
Sponsor type
Industry
First posted
Jun 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of masitinib for the treatment of mild to moderate Alzheimer's Disease. Masitinib will be administered as add-on therapy in patients who have been treated for a minimum of 6 months with a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine.

Conditions

  • Alzheimer Disease

Interventions

  • MasitinibDrug

  • PlaceboDrug

  • Standard of careDrug

    stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ADCS-ADLTime frame: 24 weeks
  2. ADAS-CogTime frame: 24 weeks

Locations

6 sites in 6 countries. Site status is shown where the registry gives one.

  • MHAT Sveta Marina

    Varna, Bulgaria

  • General Hospital of Thessaloniki

    Thessaloniki, Greece

  • Centrum Zdrowia Stołeczna 7

    Bialystok, Poland

  • Spitalul Universitar de Urgenta Elias

    Bucharest, Romania

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain

  • Municipal Institution Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov

    Dnipropetrovsk, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.